These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 26489827)

  • 1. Nonclinical Safety and Toxicology.
    Stark C; Steger-Hartmann T
    Handb Exp Pharmacol; 2016; 232():261-83. PubMed ID: 26489827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicology Strategies for Drug Discovery: Present and Future.
    Blomme EA; Will Y
    Chem Res Toxicol; 2016 Apr; 29(4):473-504. PubMed ID: 26588328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory drug safety: a discovery strategy to reduce attrition in development.
    Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
    J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.
    Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
    Drug Discov Today; 2014 Aug; 19(8):1137-44. PubMed ID: 24374152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how.
    Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
    Drug Discov Today; 2014 Aug; 19(8):1131-6. PubMed ID: 24368175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
    Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
    Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making.
    Dambach DM; Misner D; Brock M; Fullerton A; Proctor W; Maher J; Lee D; Ford K; Diaz D
    Chem Res Toxicol; 2016 Apr; 29(4):452-72. PubMed ID: 26625186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
    Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
    Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming the barriers to the uptake of nonclinical microsampling in regulatory safety studies.
    Chapman K; Chivers S; Gliddon D; Mitchell D; Robinson S; Sangster T; Sparrow S; Spooner N; Wilson A
    Drug Discov Today; 2014 May; 19(5):528-32. PubMed ID: 24448068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Pharmacology in Drug Discovery and Development.
    Morimoto BH; Castelloe E; Fox AW
    Handb Exp Pharmacol; 2015; 229():65-80. PubMed ID: 26091636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.
    McGivern JV; Ebert AD
    Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction to nonclinical safety pharmacology and the safety pharmacology society.
    Bass AS; Vargas HM; Kinter LB
    J Pharmacol Toxicol Methods; 2004; 49(3):141-4. PubMed ID: 15172009
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug discovery through stem cell-based organoid models.
    Ranga A; Gjorevski N; Lutolf MP
    Adv Drug Deliv Rev; 2014 Apr; 69-70():19-28. PubMed ID: 24582599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.
    Vargas HM; Amouzadeh HR; Engwall MJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):91-102. PubMed ID: 23170873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.
    Giri S; Bader A
    Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the safety assessment of drug-mediated changes in the QT interval... what's next?
    Pugsley MK; Authier S; Towart R; Gallacher DJ; Curtis MJ
    J Pharmacol Toxicol Methods; 2009; 60(1):24-7. PubMed ID: 19616107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicology testing in drug discovery and development.
    Dorato MA; Buckley LA
    Curr Protoc Toxicol; 2007 Feb; Chapter 19():Unit19.1. PubMed ID: 23045141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Predictive Toxicology for Discovery Safety through High Content Screening.
    Persson M; Hornberg JJ
    Chem Res Toxicol; 2016 Dec; 29(12):1998-2007. PubMed ID: 27766849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Early Safety Pharmacology Screening: Perspectives Related to Cardiovascular Safety.
    Gintant G
    Handb Exp Pharmacol; 2015; 229():47-64. PubMed ID: 26091635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.